Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry

Overview

Journal Stroke

Specialties Cardiology & Vascular Diseases
Neurology

Date 2022 Apr 20

PMID 35440169

Authors

Takeshi Yoshimoto

Kazunori Toyoda

Masafumi Ihara

Hiroshi Inoue

Takeshi Yamashita

Shinya Suzuki

Masaharu Akao

Hirotsugu Atarashi

Takanori Ikeda

Ken Okumura

Yukihiro Koretsune

Wataru Shimizu

Hiroyuki Tsutsui

Atsushi Hirayama

Masahiro Yasaka

Hirofumi Maruyama

Satoshi Teramukai

Tetsuya Kimura

Yoshiyuki Morishima

Atsushi Takita

Takenori Yamaguchi

Affiliations

Soon will be listed here.

Abstract

Background: We determined the long-term event incidence among elderly patients with nonvalvular atrial fibrillation in terms of history of stroke/transient ischemic attack (TIA) and oral anticoagulation.

Methods: Patients aged ≥75 years with documented nonvalvular atrial fibrillation enrolled in the prospective, multicenter, observational All Nippon Atrial Fibrillation in the Elderly Registry between October 2016 and January 2018 were divided into 2 groups according to history of stroke/TIA. The primary end point was the occurrence of stroke/systemic embolism within 2 years, and secondary end points were major bleeding and all-cause death within 2 years. Cox models were used to determine whether there was a difference in the hazard of each end point in patients with/without history of stroke/TIA, and in ischemic stroke/TIA survivors taking direct oral anticoagulants versus those taking warfarin.

Results: Of 32 275 evaluable patients (13 793 women [42.7%]; median age, 81.0 years), 7304 (22.6%) had a history of stroke/TIA. The patients with previous stroke/TIA were more likely to be male and older and had higher hazard rates of stroke/systemic embolism (adjusted hazard ratio, 2.25 [95% CI, 1.97-2.58]), major bleeding (1.25, 1.05-1.49), and all-cause death (1.13, 1.02-1.24) than the other groups. Of 6446 patients with prior ischemic stroke/TIA, 4393 (68.2%) were taking direct oral anticoagulants and 1668 (25.9%) were taking warfarin at enrollment. The risk of stroke/systemic embolism was comparable between these 2 groups (adjusted hazard ratio, 0.90 [95% CI, 0.71-1.14]), while the risk of major bleeding (0.67, 0.48-0.94), intracranial hemorrhage (0.57, 0.39-0.85), and cardiovascular death (0.71, 0.51-0.99) was lower among those taking direct oral anticoagulants.

Conclusions: Patients aged ≥75 years with nonvalvular atrial fibrillation and previous stroke/TIA more commonly had subsequent ischemic and hemorrhagic events than those without previous stroke/TIA. Among patients with previous ischemic stroke/TIA, the risk of hemorrhagic events was lower in patients taking direct oral anticoagulants compared with warfarin.

Registration: URL: https://www.

Clinicaltrials: gov; Unique Identifier: UMIN000024006.

Citing Articles

The stroke outcome optimization project: Acute ischemic strokes from a comprehensive stroke center.

Absher J, Goncher S, Newman-Norlund R, Perkins N, Yourganov G, Vargas J Sci Data. 2024; 11(1):839.

PMID: 39095364 PMC: 11297183. DOI: 10.1038/s41597-024-03667-5.

Relationship between maximum carotid plaque area and prognosis of patients with acute ischaemic stroke.

Fan Y, Lv Y, Fu M, Wang J, Cui Y, Zhang B Ir J Med Sci. 2024; 193(5):2501-2507.

PMID: 38890259 DOI: 10.1007/s11845-024-03739-w.

Accuracy of a Smartwatch to Assess Heart Rate Monitoring and Atrial Fibrillation in Stroke Patients.

Meza C, Juega J, Francisco J, Santos A, Duran L, Rodriguez M Sensors (Basel). 2023; 23(10).

PMID: 37430546 PMC: 10223397. DOI: 10.3390/s23104632.

Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry.

Shiozawa M, Koga M, Inoue H, Yamashita T, Yasaka M, Suzuki S Int J Stroke. 2023; 18(8):986-995.

PMID: 37154598 PMC: 10507992. DOI: 10.1177/17474930231175807.

References

Okada M, Inoue K, Tanaka N, Sakata Y, Akao M, Yamashita T . Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On-label Doses of Apixaban: J-ELD AF Registry Subanalysis. J Am Heart Assoc. 2021; 10(15):e021224. PMC: 8475673. DOI: 10.1161/JAHA.121.021224. View

Patti G, Lucerna M, Pecen L, Siller-Matula J, Cavallari I, Kirchhof P . Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). J Am Heart Assoc. 2017; 6(7). PMC: 5586290. DOI: 10.1161/JAHA.117.005657. View

Yamashita Y, Hamatani Y, Esato M, Chun Y, Tsuji H, Wada H . Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry. Chest. 2015; 149(2):401-412. DOI: 10.1378/chest.15-1095. View

Yamashita T, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T . Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes. 2021; 8(2):202-213. PMC: 8888123. DOI: 10.1093/ehjqcco/qcab025. View

Yasaka M, Yamashita T, Akao M, Atarashi H, Ikeda T, Koretsune Y . Background characteristics and anticoagulant usage patterns of elderly non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective, multicentre, observational cohort study in Japan. BMJ Open. 2021; 11(3):e044501. PMC: 7942257. DOI: 10.1136/bmjopen-2020-044501. View

Koretsune Y, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K . Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. Circ J. 2019; 83(7):1538-1545. DOI: 10.1253/circj.CJ-19-0094. View

Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K . Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. J Cardiol. 2018; 72(4):300-306. DOI: 10.1016/j.jjcc.2018.02.018. View

Hankey G, Patel M, Stevens S, Becker R, Breithardt G, Carolei A . Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012; 11(4):315-22. DOI: 10.1016/S1474-4422(12)70042-X. View

Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View

10.

Easton J, Lopes R, Bahit M, Wojdyla D, Granger C, Wallentin L . Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012; 11(6):503-11. DOI: 10.1016/S1474-4422(12)70092-3. View

11.

Kannel W, Wolf P, Benjamin E, Levy D . Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998; 82(8A):2N-9N. DOI: 10.1016/s0002-9149(98)00583-9. View

12.

Diener H, Connolly S, Ezekowitz M, Wallentin L, Reilly P, Yang S . Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010; 9(12):1157-1163. DOI: 10.1016/S1474-4422(10)70274-X. View

13.

Gage B, Waterman A, Shannon W, Boechler M, Rich M, Radford M . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285(22):2864-70. DOI: 10.1001/jama.285.22.2864. View

14.

Schulman S, Kearon C . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692-4. DOI: 10.1111/j.1538-7836.2005.01204.x. View

15.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View

16.

Wolf P, Abbott R, Kannel W . Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987; 147(9):1561-4. View

17.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

18.

Mazurek M, Shantsila E, Lane D, Wolff A, Proietti M, Lip G . Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. Stroke. 2017; 48(8):2198-2205. DOI: 10.1161/STROKEAHA.116.016146. View

19.

Senoo K, An Y, Ogawa H, Lane D, Wolff A, Shantsila E . Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. Heart. 2016; 102(23):1878-1882. DOI: 10.1136/heartjnl-2016-309741. View

20.

Halperin J, Hankey G, Wojdyla D, Piccini J, Lokhnygina Y, Patel M . Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and.... Circulation. 2014; 130(2):138-46. DOI: 10.1161/CIRCULATIONAHA.113.005008. View